Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...

Allovir Inc., which has struggled since late last December, will merge with privately held Kalaris Therapeutics Inc. to develop therapies for treating neovascular and exudative retinal diseases.

Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical ...

Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...

Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab ... and therefore, the activity of, the naturally occurring anticoagulation protein called tissue factor pathway inhibitor.

Overall, the results with Keytruda are very similar to that seen with BMS’ PD-1 inhibitor Opdivo (nivolumab), which was approved by the FDA for the ... the evidence for their drugs and support ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

The FDA has approved Genentech’s inavolisib (Itovebi) in combination with the CDK4/6 inhibitor palbociclib and the oestrogen-receptor antagonist fulvestrant for endocrine-resistant, PIK3CA ...

National Institutes of Pharmaceutical R&D Co. Ltd. has synthesized fibroblast growth factor receptor 2 (FGFR2) inhibitors reported to be useful for the treatment of cancer.

TYRA-300 is the first oral FGFR-3 selective inhibitor to be well-tolerated ... of our product candidates that may limit their development, regulatory approval, and/or commercialization; the ...

TYRA-300 is a potential first-in-class, investigational, oral, FGFR3-selective inhibitor designed ... candidates that may limit their development, regulatory approval, and/or commercialization ...